Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 310Squamous Cell Carcinoma of Head and Neck 163Head and Neck Neoplasms 145Carcinoma, Non-Small-Cell Lung 97Colonic Neoplasms 89Rectal Neoplasms 81Neoplasm Metastasis 70Neoplasms 59Pancreatic Neoplasms 40Carcinoma, Squamous Cell 38Lung Neoplasms 35Esophageal Neoplasms 25Breast Neoplasms 22Stomach Neoplasms 20Recurrence 20Laryngeal Neoplasms 17Carcinoma 17Tongue Neoplasms 16Mouth Neoplasms 16Esophageal Squamous Cell Carcinoma 14Oropharyngeal Neoplasms 13Salivary Gland Neoplasms 12Adenocarcinoma Of Esophagus 12Hypopharyngeal Neoplasms 11Laryngeal Diseases 10Adenocarcinoma of Lung 10Uterine Cervical Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 9Ovarian Neoplasms 9Nasopharyngeal Carcinoma 9

Interventions

Cyclophosphamide 22blinatumomab 18Cytarabine 15fludarabine 13Azacitidine 12venetoclax 10fludarabine phosphate 10Rituximab 8Lenalidomide 7Dexamethasone 7Methotrexate 6Daunorubicin 6Mercaptopurine 5daratumumab 4Whole-Body Irradiation 4Vincristine 4Melphalan 4Idarubicin 4Etoposide 4Busulfan 4pembrolizumab 3obinutuzumab 3Radiotherapy 3Maintenance 3Immunotherapy, Adoptive 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Drug Therapy 3Cladribine 3Asparaginase 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasm, Residual × Cetuximab × Clear all
NCT06358430 2026-05-20

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

M.D. Anderson Cancer Center

Phase 1 Recruiting
42 enrolled
Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡